NCT01821560

Baclofen Effects in Cigarette Smokers

Baclofen Effects on Brain and Behavior in Cigarette Smokers

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome.

Conditions

• Nicotine Dependence

Interventions

Type	Name	Description
DRUG	Baclofen
DRUG	placebo

Timeline

• Start date: 2013-03-01
• Primary completion: 2017-06-01
• Completion: 2017-06-01
• First posted: 2013-04-01
• Last updated: 2018-12-19
• Results posted: 2018-12-19

Locations

1 site across 1 country: United States